Firefly Neuroscience Seeks Shareholder Nod for 98% Cut in Authorized Shares and Equity Plan Top-Up

summarizeSummary

Firefly Neuroscience's proxy seeks approval to cut authorized shares from 5 billion to 101 million to reduce franchise taxes, and to add 2 million shares to its equity incentive plan. The meeting is August 5, 2026.

check_boxKey Events · Corporate Governance and Compliance · AIFF

• Authorized Share Reduction

  Proposal 5 would reduce authorized shares from 5,001,000,000 to 101,000,000 (100M common, 1M preferred), a 98% cut, to lower Delaware franchise taxes.

• Equity Plan Expansion

  Proposal 4 seeks to add 2,000,000 shares to the 2024 Long-Term Incentive Plan, increasing the pool to 3,707,496 shares. Only 412,614 shares remain available for grant.

• Director Election

  Proposal 1 elects Arun Menawat as Class III director for a term expiring in 2029.

• Auditor Ratification

  Proposal 2 ratifies CBIZ Canada, LLP (formerly Marcum Canada) as independent auditor for fiscal 2026.

auto_awesomeAnalysis · AIFF · Technology

The definitive proxy for Firefly Neuroscience's August 5, 2026 annual meeting puts forward two proposals that go straight to the heart of the company's capital structure and equity compensation capacity. Proposal 5 would slash authorized shares from 5 billion to 101 million — a 98% reduction — primarily to trim Delaware franchise taxes, a cash-conservation tactic for a firm carrying a going-concern warning and a market cap of just $19 million. Meanwhile, Proposal 4 asks shareholders to greenlight 2 million additional shares for the 2024 Long-Term Incentive Plan, lifting the pool to 3.7 million shares. While the authorized share cut reads as a governance cleanup, the equity plan expansion, if fully utilized, could prove dilutive given the company's small size and a recent history of highly dilutive financings. The proxy also covers routine items: election of one director, auditor ratification, say-on-pay, and adjournment authority. The meeting is set for August 5, 2026.